GR3025698T3 - NOVEL GABAa RECEPTOR SUBTYPES AND METHODS FOR SCREENING DRUG COMPOUNDS USING IMIDAZOQUINOXALINES AND PYRROLOPYRIMIDINES TO BIND TO GABAa RECEPTOR SUBTYPES. - Google Patents
NOVEL GABAa RECEPTOR SUBTYPES AND METHODS FOR SCREENING DRUG COMPOUNDS USING IMIDAZOQUINOXALINES AND PYRROLOPYRIMIDINES TO BIND TO GABAa RECEPTOR SUBTYPES.Info
- Publication number
- GR3025698T3 GR3025698T3 GR970403349T GR970403349T GR3025698T3 GR 3025698 T3 GR3025698 T3 GR 3025698T3 GR 970403349 T GR970403349 T GR 970403349T GR 970403349 T GR970403349 T GR 970403349T GR 3025698 T3 GR3025698 T3 GR 3025698T3
- Authority
- GR
- Greece
- Prior art keywords
- receptor subtypes
- gabaa receptor
- methods
- imidazoquinoxalines
- pyrrolopyrimidines
- Prior art date
Links
- 102000027484 GABAA receptors Human genes 0.000 title abstract 3
- 108091008681 GABAA receptors Proteins 0.000 title abstract 3
- 150000001875 compounds Chemical class 0.000 title abstract 3
- 238000000034 method Methods 0.000 title abstract 3
- 238000012216 screening Methods 0.000 title abstract 2
- 208000031752 chronic bilirubin encephalopathy Diseases 0.000 title 1
- 239000003814 drug Substances 0.000 title 1
- 229940079593 drug Drugs 0.000 title 1
- 150000004944 pyrrolopyrimidines Chemical class 0.000 title 1
- 230000001225 therapeutic effect Effects 0.000 abstract 1
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/94—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving narcotics or drugs or pharmaceuticals, neurotransmitters or associated receptors
- G01N33/9406—Neurotransmitters
- G01N33/9426—GABA, i.e. gamma-amino-butyrate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B59/00—Introduction of isotopes of elements into organic compounds ; Labelled organic compounds per se
- C07B59/002—Heterocyclic compounds
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
- C07D471/14—Ortho-condensed systems
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/566—Immunoassay; Biospecific binding assay; Materials therefor using specific carrier or receptor proteins as ligand binding reagents where possible specific carrier or receptor proteins are classified with their target compounds
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/94—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving narcotics or drugs or pharmaceuticals, neurotransmitters or associated receptors
- G01N33/948—Sedatives, e.g. cannabinoids, barbiturates
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2500/00—Screening for compounds of potential therapeutic value
- G01N2500/20—Screening for compounds of potential therapeutic value cell-free systems
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Molecular Biology (AREA)
- Biomedical Technology (AREA)
- Immunology (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Food Science & Technology (AREA)
- Pharmacology & Pharmacy (AREA)
- Analytical Chemistry (AREA)
- Biochemistry (AREA)
- Physics & Mathematics (AREA)
- General Physics & Mathematics (AREA)
- Biotechnology (AREA)
- Cell Biology (AREA)
- Pathology (AREA)
- Microbiology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- General Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Anesthesiology (AREA)
- Pain & Pain Management (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US07/876,050 US5597920A (en) | 1992-04-30 | 1992-04-30 | Gabaa receptor subtypes and methods for screening drug compounds using imidazoquinoxalines and pyrrolopyrimidines to bind to gabaa receptor subtypes |
| PCT/US1993/003920 WO1993022681A1 (en) | 1992-04-30 | 1993-04-30 | NOVEL GABAa RECEPTOR SUBTYPES AND METHODS FOR SCREENING DRUG COMPOUNDS USING IMIDAZOQUINOXALINES AND PYRROLOPYRIMIDINES TO BIND TO GABAa RECEPTOR SUBTYPES |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| GR3025698T3 true GR3025698T3 (en) | 1998-03-31 |
Family
ID=25366890
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| GR970403349T GR3025698T3 (en) | 1992-04-30 | 1997-12-17 | NOVEL GABAa RECEPTOR SUBTYPES AND METHODS FOR SCREENING DRUG COMPOUNDS USING IMIDAZOQUINOXALINES AND PYRROLOPYRIMIDINES TO BIND TO GABAa RECEPTOR SUBTYPES. |
Country Status (12)
| Country | Link |
|---|---|
| US (2) | US5597920A (el) |
| EP (1) | EP0639275B1 (el) |
| JP (1) | JPH08500333A (el) |
| KR (1) | KR950702032A (el) |
| AT (1) | ATE158414T1 (el) |
| AU (1) | AU691470B2 (el) |
| CA (1) | CA2134227A1 (el) |
| DE (1) | DE69314024T2 (el) |
| DK (1) | DK0639275T3 (el) |
| ES (1) | ES2110090T3 (el) |
| GR (1) | GR3025698T3 (el) |
| WO (1) | WO1993022681A1 (el) |
Families Citing this family (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6010861A (en) * | 1994-08-03 | 2000-01-04 | Dgi Biotechnologies, Llc | Target specific screens and their use for discovering small organic molecular pharmacophores |
| ATE223576T1 (de) * | 1996-10-25 | 2002-09-15 | Neurosearch As | Methode zur identifizierung von verbindungen mit anxiolytischem potential |
| US6737242B1 (en) | 1999-05-07 | 2004-05-18 | Neurogen Corporation | Methods for screening GABA-modulatory compounds for specified pharmacological activities |
| AU4703200A (en) * | 1999-05-07 | 2000-11-21 | Neurogen Corporation | Methods for screening gaba-modulatory compounds for specified pharmacological activities |
| US7473691B2 (en) | 2000-09-15 | 2009-01-06 | Vertex Pharmaceuticals Incorporated | Pyrazole compounds useful as protein kinase inhibitors |
| ZA200301703B (en) * | 2000-09-15 | 2004-03-02 | Vertex Pharma | Pyrazole compounds useful as protein kinase inhibitors. |
| US6660731B2 (en) | 2000-09-15 | 2003-12-09 | Vertex Pharmaceuticals Incorporated | Pyrazole compounds useful as protein kinase inhibitors |
| HUP0302173A2 (hu) * | 2000-09-15 | 2003-09-29 | Vertex Pharmaceuticals Incorporated | Protein kináz inhibitorokként alkalmazható pirazolvegyületek |
| SI1318997T1 (sl) * | 2000-09-15 | 2006-12-31 | Vertex Pharma | Pirazolne spojine, uporabne kot inhibitorji protein-kinaze |
| ES2265452T3 (es) | 2000-12-21 | 2007-02-16 | Vertex Pharmaceuticals Incorporated | Compuestos de pirazol utiles como inhibidores de la proteina quinasa. |
| US20040009981A1 (en) | 2002-03-15 | 2004-01-15 | David Bebbington | Compositions useful as inhibitors of protein kinases |
| MY141867A (en) | 2002-06-20 | 2010-07-16 | Vertex Pharma | Substituted pyrimidines useful as protein kinase inhibitors |
| WO2004013140A1 (en) | 2002-08-02 | 2004-02-12 | Vertex Pharmaceuticals Incorporated | Pyrazole compositions useful as inhibitors of gsk-3 |
| AR056763A1 (es) | 2005-11-03 | 2007-10-24 | Vertex Pharma | Aminopirimidinas sustituidas con tiazol o pirazol,utiles como agentes anticancer y composiciones farmaceuticas que las contienen. |
| CA2685876A1 (en) | 2007-05-02 | 2008-11-13 | Vertex Pharmaceuticals Incorporated | Thiazoles and pyrazoles useful as kinase inhibitors |
| WO2009018415A1 (en) | 2007-07-31 | 2009-02-05 | Vertex Pharmaceuticals Incorporated | Process for preparing 5-fluoro-1h-pyrazolo [3, 4-b] pyridin-3-amine and derivatives thereof |
| EP2323622A1 (en) | 2008-09-03 | 2011-05-25 | Vertex Pharmaceuticals Incorporated | Co-crystals and pharmaceutical formulations comprising the same |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SE7900456L (sv) * | 1978-05-31 | 1979-07-20 | Ferrosan As | Bensodiazeptinkoncentrationsbestemning |
| IL90315A0 (en) * | 1988-06-01 | 1989-12-15 | Ferrosan As | Imidazoquinoxaline compounds,their preparation and pharmaceutical compositions containing them |
| US5185446A (en) * | 1990-09-04 | 1993-02-09 | Neurogen Corporation | Certain cycloalkyl imidazopyrimidines; a new class of gaba brainreceptor ligands |
| CA2091986C (en) * | 1990-10-09 | 1995-11-28 | Andrew Thurkauf | Certain cycloalkyl and azacycloalkyl pyrrolopyrimidines; a new class of gaba brain receptor ligands |
| US5130430A (en) * | 1990-10-31 | 1992-07-14 | Neurogen Corporation | 2-substituted imidazoquinoxaline diones, a new class of gaba brain receptor ligands |
| WO1994025463A1 (en) * | 1992-04-08 | 1994-11-10 | Neurogen Corporation | Certain aryl fused pyrrolopyrimidines; a new class of gaba brain receptor ligands |
-
1992
- 1992-04-30 US US07/876,050 patent/US5597920A/en not_active Expired - Fee Related
-
1993
- 1993-04-30 EP EP93910819A patent/EP0639275B1/en not_active Expired - Lifetime
- 1993-04-30 AU AU41177/93A patent/AU691470B2/en not_active Ceased
- 1993-04-30 US US08/331,501 patent/US5688654A/en not_active Expired - Fee Related
- 1993-04-30 AT AT93910819T patent/ATE158414T1/de not_active IP Right Cessation
- 1993-04-30 ES ES93910819T patent/ES2110090T3/es not_active Expired - Lifetime
- 1993-04-30 DE DE69314024T patent/DE69314024T2/de not_active Expired - Fee Related
- 1993-04-30 DK DK93910819.7T patent/DK0639275T3/da active
- 1993-04-30 CA CA002134227A patent/CA2134227A1/en not_active Abandoned
- 1993-04-30 WO PCT/US1993/003920 patent/WO1993022681A1/en active IP Right Grant
- 1993-04-30 KR KR1019940703877A patent/KR950702032A/ko not_active Application Discontinuation
- 1993-04-30 JP JP5519445A patent/JPH08500333A/ja active Pending
-
1997
- 1997-12-17 GR GR970403349T patent/GR3025698T3/el unknown
Also Published As
| Publication number | Publication date |
|---|---|
| AU691470B2 (en) | 1998-05-21 |
| US5688654A (en) | 1997-11-18 |
| AU4117793A (en) | 1993-11-29 |
| EP0639275A1 (en) | 1995-02-22 |
| KR950702032A (ko) | 1995-05-17 |
| US5597920A (en) | 1997-01-28 |
| WO1993022681A1 (en) | 1993-11-11 |
| EP0639275B1 (en) | 1997-09-17 |
| DK0639275T3 (da) | 1998-04-14 |
| DE69314024T2 (de) | 1998-04-16 |
| CA2134227A1 (en) | 1993-11-11 |
| JPH08500333A (ja) | 1996-01-16 |
| ES2110090T3 (es) | 1998-02-01 |
| DE69314024D1 (de) | 1997-10-23 |
| ATE158414T1 (de) | 1997-10-15 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| GR3025698T3 (en) | NOVEL GABAa RECEPTOR SUBTYPES AND METHODS FOR SCREENING DRUG COMPOUNDS USING IMIDAZOQUINOXALINES AND PYRROLOPYRIMIDINES TO BIND TO GABAa RECEPTOR SUBTYPES. | |
| PL331091A1 (en) | Therapeutic multispecific compounds encompassing antibodies against the fcalpha receptor | |
| ES2164657T3 (es) | Derivados aza-biciclicos puenteados como antagonistas de la sustancia p. | |
| HUP9802483A3 (en) | Soluble lymphotoxin-beta receptors and anti-lymphotoxin receptor and ligand antibodies, as therapeutic agents for the treatment of immunological disease | |
| BG101806A (en) | Indole derivatives as 5-ht receptor antagoniss | |
| ZA946142B (en) | Therapeutic heterocycles | |
| NO20003534D0 (no) | Progesteronreseptor-modulatorforbindelser, farmasøytiske sammensetninger inneholdende disse og anvendelsen av forbindelsene | |
| TR200001603T2 (tr) | Yeni bileşikler | |
| ATE38232T1 (de) | Metallocene und photopolymerisierbare zusammensetzung, enthaltend diese metallocene. | |
| MX9704640A (es) | Compuesto moduladores de los receptores de los esteroides y metodos para su preparacion. | |
| ATE298230T1 (de) | Verwendung einer sich an periphere benzodiazepinrezeptoren bindenden substanz zur behandlung von hautstress | |
| AU3117795A (en) | Spiro{indoline-{2,3'}-benzoxazine}-type photochromic compounds containing a 6'-cyano or phenylsulphonyl group and with a 7', 8'-condensed benzene ring in the benzoxazine ring and use of same in ophthalmic optics | |
| ATE238800T1 (de) | Verwendung von squalamin zur herstellung eines arzneimittels zur inhibierung von nhe | |
| ATE205480T1 (de) | 2,5-dioxo-2,5-dihydro-1h-benz(b)azepine als nmda rezeptor antagonisten | |
| HUP9904516A3 (en) | Soluble lymphotoxin-betha receptors, anti-lymphotoxin receptor antibodies, and anti-lymphotoxin ligand antibodies as therapeutic agents for the treatment of immunological diseases | |
| AU3745795A (en) | Use of CCK-B receptor antagonists for the treatment of sleepdisorders | |
| DE69412073D1 (de) | Xanthinderivate als adenosin-a1 rezeptor antagonisten | |
| TR199801659T2 (xx) | Yeni triazolopurinler, haz�rlama y�ntemi, ila� olarak kullan�m�. | |
| ATE217619T1 (de) | Endothelin-rezeptor-antagonisten | |
| ATE153027T1 (de) | Zuckerderivate von makroliden | |
| EP0462468A3 (en) | 9-amino-2-phenylbicyclo(3.3.1)nonane and 9-amino-2-phenylbicyclo(3.3.1)-non-2-ene and therapeutic agents containing them | |
| SI0954333T1 (sl) | Topni limfotoksin-beta receptorji, anti-limfotoksin receptorska protitelesa in anti-limfotoksin ligandna protitelesa kot terapevtska sredstva za zdravljenje imunoloskih bolezni |